Biotechnology

Ensysce Biosciences

Ensysce Biosciences Initiates Phase 3 Clinical Trial for PF614

Ensysce Biosciences released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 493.1K (forecast USD 1.399M), actual EPS USD -1.2921 (forecast USD -0.76)

Ensysce Biosciences released FY2025 9 Months Earnings on November 14 EST with actual revenue of USD 3.184 M and EPS of USD -3.4677

Ensysce Announces Phase III Clinical Trial for PF614

Ensysce Biosciences released FY2025 Semi-Annual Earnings on August 13 (EST), actual revenue USD 2.691M, actual EPS USD -2.04

Ensysce Biosciences released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 1.371 M (forecast USD 673.08 K), actual EPS USD -0.787 (forecast USD -1.015)

Ensysce Initiates PF614's Critical Phase III Study

Ensysce Biosciences Launches Innovative Opioid Drug Product

Ensysce Biosciences Inc Completes Recruitment for Phase II of PF614-MPAR-102 Clinical Study

Ensysce Biosciences Inc Reports Improved Quarterly EPS and Soars Revenue

Ensysce Biosciences released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 1.32 M (forecast USD 0), actual EPS USD -1.3885 (forecast USD -3.015)

Ensysce Biosciences Completes Warrant Exercise for $2.2 Million

Ensysce Reports Positive PF614-MPAR Clinical Trial Results

Ensysce Biosciences released FY2024 Q4 earnings on March 10 (EST), actual revenue 1.304 M USD (forecast 245 K USD), actual EPS -2.9 USD (forecast -2.735 USD)

Ensysce Biosciences released FY2024 annual earnings on March 10 (EST), actual revenue 5.21 M USD (forecast 4.15 M USD), actual EPS -11.4481 USD (forecast -12.4499 USD)

Ensysce Biosciences released FY2024 Q3 earnings on November 12 (EST), actual revenue 3.419 M USD (forecast 200 K USD), actual EPS 1.0036 (forecast -0.17)

Ensysce Biosciences released FY2024 9 Months Earnings on November 12 (EST), actual revenue USD 3.906 M, actual EPS USD -10.5546

Ensysce Biosciences Receives Federal Funding, PF614-MPAR Clinical Trial Surges 62%

Ensysce Biosciences released FY2024 Semi-Annual earnings on August 14 (EST), actual revenue USD 487.52K, actual EPS USD -9.9825

Ensysce Biosciences released FY2024 Q2 earnings on August 14 (EST), actual revenue 181.8K USD (forecast 300K USD), actual EPS -3.3476 (forecast -0.33)

Intelligent Bio Solutions

Anghami

ESH Acquisition

Sidus Space

ESH ACQUISITION CORP COM USD0.0001 CL A (S/R 13/06/2028)

Northann

RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT)

Vanda Pharma

Oriental Rise

Urgently

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Ensysce Biosciences(ENSC.US)